(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why. - 2Is relief in sight? Flu season still brutal but cases are declining.
- 3NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- 4The capacity to understand people on a profound level: Exploring Life's Intricacies
- 5French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
- Building a Flourishing Business: Illustrations from Business people
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- How is 'A Knight of the Seven Kingdoms' connected to 'Game of Thrones'?
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
- Finding Ideal Date Spots for Two or three Encounters
